PIII Stock Price, P3 Health Partners Inc. Quote, Chart

Market Summary

USD0.600.00

Delayed

0.00%

PIII Stock Price

View Fullscreen

PIII RSI Chart

PIII Valuation

Market Cap

71.3M

Price/Earnings (Trailing)

-1.06

Price/Sales (Trailing)

0.05

EV/EBITDA

-1.45

Price/Free Cashflow

-0.97

PIII Price/Sales (Trailing)

PIII Profitability

EBT Margin

-13.24%

Return on Equity

-45.89%

Return on Assets

-7.86%

Free Cashflow Yield

-103.32%

PIII Fundamentals

PIII Revenue

Revenue (TTM)

1.4B

Rev. Growth (Yr)

28.61%

Rev. Growth (Qtr)

12%

PIII Earnings

Earnings (TTM)

-67.3M

Earnings Growth (Yr)

-103.28%

Earnings Growth (Qtr)

26.56%

Breaking Down PIII Revenue

Last 7 days

-10.4%

Last 30 days

20%

Last 90 days

-42.3%

Trailing 12 Months

-81.2%

How does PIII drawdown profile look like?

PIII Financial Health

Current Ratio

0.55

Debt/Equity

0.81

Debt/Cashflow

-0.61

PIII Investor Care

Shares Dilution (1Y)

128.21%

Diluted EPS (TTM)

-0.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.4B	0	0	0
2023	1.1B	1.1B	1.2B	1.3B
2022	766.9M	861.1M	955.3M	1.0B
2021	517.6M	549.6M	576.9M	578.6M
2020	230.8M	315.7M	400.6M	485.5M
2019	0	0	0	145.9M
2018	0	0	0	87.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of P3 Health Partners Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 09, 2024	bacchus amir	acquired	-	-	287,118	chief medical officer
Jan 09, 2024	abdou sherif	acquired	-	-	483,868	chief executive officer
Dec 31, 2023	bacchus amir	sold (taxes)	-404,836	1.41	-287,118	chief medical officer
Dec 31, 2023	abdou sherif	sold (taxes)	-682,254	1.41	-483,868	chief executive officer
Oct 23, 2023	wasson gregory d	acquired	-	-	216,561	-
Oct 23, 2023	tolan mary a	acquired	-	-	216,561	-
Oct 23, 2023	price thomas edmunds	acquired	-	-	216,561	-
Oct 23, 2023	leisure lawrence b.	acquired	-	-	216,561	-
Oct 23, 2023	kazarian gregory n.	acquired	-	-	216,561	-
Oct 23, 2023	park jeffrey g	acquired	-	-	216,561	-

Which funds bought or sold PIII recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-84.55	-120,476	15,327	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-29.87	-4,618	4,850	-%
May 15, 2024	Royal Bank of Canada	reduced	-92.7	-17,000	1,000	-%
May 15, 2024	DEUTSCHE BANK AG\	unchanged	-	-7,174	19,445	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-74,638	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-82.54	-615,237	89,965	-%
May 15, 2024	Mariner, LLC	new	-	35,089	35,089	-%
May 15, 2024	Walleye Trading LLC	added	22.33	-5,783	48,556	-%
May 15, 2024	Walleye Trading LLC	unchanged	-	-2,185	8,130	-%
May 15, 2024	TENOR CAPITAL MANAGEMENT Co., L.P.	unchanged	-	-2,233	8,312	-%

Are Funds Buying or Selling PIII?

Are funds buying PIII calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PIII

No. of Funds

Unveiling P3 Health Partners Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 27, 2024	ameriprise financial inc	4.72%	5,441,489	SC 13G/A
Feb 14, 2024	ameriprise financial inc	4.72%	5,441,489	SC 13G/A
Feb 13, 2024	vanguard group inc	1.35%	1,560,655	SC 13G/A
Feb 12, 2024	lmr partners llp	2.2%	2,546,924	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Nov 03, 2023	abdou sherif	2.5%	7,907,484	SC 13D/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
Apr 21, 2023	chicago pacific founders ugp, llc	34.71%	110,415,418	SC 13D/A
Apr 19, 2023	leavitt equity partners ii, l.p.	14.9%	9,070,678	SC 13D/A
Apr 14, 2023	bacchus amir	8.6%	20,989,518	SC 13D/A

Recent SEC filings of P3 Health Partners Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	3	Insider Trading
May 13, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
May 09, 2024	DEFA14A	DEFA14A
May 09, 2024	S-8	Employee Benefits Plan
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Mar 28, 2024	10-K	Annual Report

Peers (Alternatives to P3 Health Partners Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

P3 Health Partners Inc. News

Latest updates

P3 Health Partners Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Revenue	12.0%	388,488,000	346,861,000	288,351,000	329,086,000	302,077,000	258,213,000	248,260,000	269,454,000	273,544,000	200,037,831	126,531,662	156,185,955	144,586,444	151,297,940	124,877,011	128,840,991	-	-	-	-
Operating Expenses	5.2%	432,319,000	411,121,000	322,171,000	350,119,000	350,894,000	794,760,000	308,271,000	1,181,641,000	325,712,000	7,000,000	188,506,629	184,309,497	170,557,507	164,286,370	2,286	142,355,570	-	-	-	-
S&GA Expenses	-55.3%	322,000	721,000	654,000	857,000	1,001,000	1,705,000	1,118,000	1,408,000	865,000	-	21,629,657	491,418	356,501	270,241	2,286	278,663	-	-	-	-
EBITDA Margin	10.1%	-0.08	-0.09	-0.49	-0.53	-1.37	-1.41	-0.16	-0.18	-0.20	-0.23	-0.27	-0.06	-0.06	-0.06	-0.07	-0.11	-0.14	-0.19	-0.30	-
Interest Expenses	-5.2%	-4,256,000	-4,046,000	-4,002,000	-3,851,000	-4,086,000	-2,986,000	-2,963,000	-2,700,000	-2,755,000	-	-2,800,815	-2,529,133	-2,369,764	-2,124,286	4,344,439	-2,316,579	-	-	-	-
Income Taxes	17.3%	2,072,000	1,767,000	412,000	226,000	290,000	1,862,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	29.4%	-47,534,000	-67,340,000	-36,877,000	-27,356,000	-52,158,000	-530,470,000	-65,329,000	-903,106,000	-60,790,000	-	-60,230,517	-32,054,361	-29,464,410	-24,650,712	-	-	-	-	-	-
EBT Margin	8.7%	-0.13	-0.15	-0.55	-0.59	-1.44	-1.49	-0.15	-0.17	-0.19	-0.22	-0.25	-0.05	-0.06	-0.06	-0.06	-0.10	-0.13	-0.18	-0.29	-
Net Income	26.6%	-18,700,000	-25,462,000	-13,296,000	-9,816,000	-9,199,000	-94,027,000	-11,173,000	-154,350,000	-10,577,000	-	61,364,359	-32,054,361	-29,464,410	-24,650,712	-2,286	-875,560	-2,774,562	1,550,953	-	-
Net Income Margin	-9.0%	-0.05	-0.05	-0.11	-0.11	-0.25	-0.26	-0.03	-0.03	-0.03	-0.04	-0.04	-0.15	-0.10	-0.05	0.00	-0.10	-0.13	-0.18	-0.29	-0.50
Free Cashflow	-27.9%	-20,030,000	-15,666,000	-7,973,000	-30,030,000	-24,186,000	-31,904,000	-21,859,000	-45,836,000	-28,653,000	37,941,032	37,941,032	-6,802,469	-22,237,214	-13,777,897	-18,644,652	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-0.6%	856	861	897	909	867	877	1,383	1,444	2,357	2,364	317	79.00	317	233	149	66.00
Current Assets	10.2%	183	166	180	172	109	101	124	171	213	200	0.00	54.00	1.00	79.00	0.00	52.00
Cash Equivalents	-11.1%	32.00	36.00	53.00	60.00	7.00	18.00	35.00	64.00	111	141	0.00	4.00	16.00	22.00	0.00	33.00
Net PPE	-6.5%	8.00	9.00	9.00	10.00	9.00	9.00	10.00	8.00	8.00	8.00	-	8.00	-	-	6.00	4.00
Goodwill	-	-	-	-	-	-	-	463	458	1,310	1,310	1,278	6.00	3.00	3.00	1.00	1.00
Liabilities	10.1%	470	427	396	378	396	354	331	329	342	300	35.00	203	16.00	6.00	40.00	74.00
Current Liabilities	11.4%	334	299	267	250	270	242	227	229	234	199	21.00	119	0.00	0.00	0.00	55.00
Short Term Borrowings	-	1.00	-	-	-	-	-	-	1.00	2.00	4.00	-	-	-	-	-	-
Long Term Debt	9.1%	118	108	108	108	108	94.00	80.00	80.00	80.00	80.00	-	59.00	-	45.00	45.00	15.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	0.00	0.00	-	0.00	-	0.00	0.00	2.00
LT Debt, Non Current	-100.0%	-	108	108	108	108	94.00	80.00	80.00	80.00	80.00	-	59.00	-	45.00	45.00	15.00
Shareholder's Equity	3.1%	147	142	188	-	-2.68	6.00	78.00	109	263	274	284	-	5.00	5.00	0.00	-
Retained Earnings	-5.1%	-386	-367	-341	-328	-318	-309	-215	-204	-50.00	-39.42	-34.19	-0.97	-184	10.00	0.00	-85.17
Additional Paid-In Capital	4.5%	533	509	530	192	316	315	294	313	313	313	-	-	-10.71	-0.18	0.00	-
Accumulated Depreciation	9.0%	5.00	5.00	-	-	-	3.00	2.00	1.00	1.00	0.00	-	-	-	-	2.00	-
Shares Outstanding	25.3%	119	95.00	88.00	107	42.00	42.00	42.00	42.00	42.00	-	-	68.00	-	-	66.00	48.00
Float	-	-	-	-	117	-	-	-	93.00	-	-	-	-	248	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Cashflow From Operations	-26.1%	-20,030	-15,878	-7,586	-28,842	-23,722	-31,954	-20,977	-45,312	-27,776	-	38,241	-5,695	-21,010	-13,121	-17,950	-	-	-	-	-
Share Based Compensation	-15.8%	1,449	1,720	2,251	1,031	977	2,193	1,784	3,716	11,711	-	2,322	355	564	461	-203	-	-	-	-	-
Cashflow From Investing	-100.0%	-	212	-387	-1,188	-464	50.00	-6,382	-252	-1,149	-	-308,365	-6,145	-1,008	-729	-1,269	-	-	-	-	-
Cashflow From Financing	1457.3%	11,401	-840	-86.00	87,156	14,102	15,000	-1,179	-1,239	-1,207	-	305,266	-22.59	12,536	-22.22	180	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PIII Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
OPERATING REVENUE:
TOTAL OPERATING REVENUE	$ 388,488	$ 302,077
OPERATING EXPENSE:
Medical expense	382,057	285,570
Premium deficiency reserve	1,000	5,140
Corporate, general and administrative expense	27,401	37,643
Sales and marketing expense	322	1,001
Depreciation and amortization	21,539	21,540
TOTAL OPERATING EXPENSE	432,319	350,894
OPERATING LOSS	(43,831)	(48,817)
OTHER INCOME (EXPENSE):
Interest expense, net	(4,256)	(4,086)
Mark-to-market of stock warrants	216	649
Other	337	96
TOTAL OTHER EXPENSE	(3,703)	(3,341)
LOSS BEFORE INCOME TAXES	(47,534)	(52,158)
PROVISION FOR INCOME TAXES	(2,072)	(290)
NET LOSS	(49,606)	(52,448)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST	(30,906)	(43,249)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST	$ (18,700)	$ (9,199)
NET LOSS PER SHARE (Note 9):
Basic (in dollars per share)	$ (0.16)	$ (0.22)
Diluted (in dollars per share)	$ (0.16)	$ (0.22)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):
Basic (in shares)	118,887	41,579
Diluted (in shares)	118,887	41,579
Capitated revenue
OPERATING REVENUE:
TOTAL OPERATING REVENUE	$ 384,134	$ 298,704
Other patient service revenue
OPERATING REVENUE:
TOTAL OPERATING REVENUE	$ 4,354	$ 3,373

PIII Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

CURRENT ASSETS:

Cash

$ 27,300

$ 36,320

Restricted cash

5,005

4,614

Health plan receivable, net of allowance for credit losses of $150

143,695

118,497

Clinic fees, insurance and other receivable

48

2,973

Prepaid expenses and other current assets

6,909

3,613

TOTAL CURRENT ASSETS

182,957

166,017

Property and equipment, net

8,121

8,686

Intangible assets, net

645,703

666,733

Other long-term assets

19,144

19,531

TOTAL ASSETS

^[1]

855,925

860,967

CURRENT LIABILITIES:

Accounts payable

11,603

8,663

Accrued expenses and other current liabilities

28,628

36,884

Accrued payroll

5,048

3,506

Health plan settlements payable

22,048

34,992

Claims payable

222,177

178,009

Premium deficiency reserve

14,670

13,670

Accrued interest

28,035

23,648

Short-term debt

1,441

0

TOTAL CURRENT LIABILITIES

333,650

299,372

Operating lease liability

12,944

13,622

Warrant liabilities

869

1,085

Contingent consideration

4,907

Long-term debt, net

118,123

108,319

TOTAL LIABILITIES

^[1]

470,493

427,305

COMMITMENTS AND CONTINGENCIES (Note 12)

MEZZANINE EQUITY:

Redeemable non-controlling interest

238,836

291,532

STOCKHOLDERS’ EQUITY:

Additional paid in capital

532,608

509,442

Accumulated deficit

(386,044)

(367,344)

TOTAL STOCKHOLDERS’ EQUITY

146,596

142,130

TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY

855,925

860,967

Class A Common Stock

STOCKHOLDERS’ EQUITY:

Common stock

12

Class V Common Stock

STOCKHOLDERS’ EQUITY:

Common stock

$ 20

[1]

The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 13 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC’s consolidated VIEs totaling $10.5 million and $8.6 million as of March 31, 2024 and December 31, 2023, respectively, and total liabilities of P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $14.9 million and $13.6 million as of March 31, 2024 and December 31, 2023, respectively. These VIE assets and liabilities do not include $44.6 million and $44.2 million of net amounts due to affiliates as of March 31, 2024 and December 31, 2023, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets.

About P3 Health Partners Inc.

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

CEO	Dr. Sherif Abdou F.A.C.E.P., FACP, M.D.
WEBSITE	https://p3hp.org
INDUSTRY	Healthcare Plans
EMPLOYEES	600

P3 Health Partners Inc. Frequently Asked Questions

What is the ticker symbol for P3 Health Partners Inc.? What does PIII stand for in stocks?

PIII is the stock ticker symbol of P3 Health Partners Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of P3 Health Partners Inc. (PIII)?

As of Fri May 17 2024, market cap of P3 Health Partners Inc. is 71.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PIII stock?

You can check PIII's fair value in chart for subscribers.

What is the fair value of PIII stock?

You can check PIII's fair value in chart for subscribers. The fair value of P3 Health Partners Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of P3 Health Partners Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PIII so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is P3 Health Partners Inc. a good stock to buy?

The fair value guage provides a quick view whether PIII is over valued or under valued. Whether P3 Health Partners Inc. is cheap or expensive depends on the assumptions which impact P3 Health Partners Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIII.

What is P3 Health Partners Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PIII's PE ratio (Price to Earnings) is -1.06 and Price to Sales (PS) ratio is 0.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIII PE ratio will change depending on the future growth rate expectations of investors.